Suppr超能文献

阿莫西林与克拉维酸联合使用相关的急性肝损伤风险。

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid.

作者信息

García Rodríguez L A, Stricker B H, Zimmerman H J

机构信息

Centro Español de Investigación Farmacoepidemiológica, Universidad Complutense de Madrid, Spain.

出版信息

Arch Intern Med. 1996 Jun 24;156(12):1327-32. doi: 10.1001/archinte.1996.00440110099013.

Abstract

BACKGROUND

Amoxicillin-clavulanic acid combination-associated hepatitis and jaundice was first identified in 1988. Numerous case reports and case series have been published since then, but there is no precise estimate of this risk.

METHODS

A retrospective cohort study in the United Kingdom to estimate the risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid and compare it with the one of amoxicillin alone. Data were derived from a cohort of 93,433 users of the combination drug amoxicillin-clavulanic acid and 360,333 users of amoxicillin alone who were aged between 10 and 79 years and who were followed up from 1991 through 1992. After reviewing the information on subjects with suspected liver injury that was recorded on computer files, the clinical records of 177 patients from the attending general practitioners were requested.

RESULTS

They were 35 cases of idiopathic acute liver injury. None was fatal. There were 14 cases of acute liver injury among users of amoxicillin alone. The type of liver injury was hepatocellular in half the cases. There were 21 cases of acute liver injury among users of amoxicillin and clavulanic acid together. The type of liver injury was cholestatic in three quarters of the cases. The incidence rates and 95% confidence intervals (CIs) of developing acute liver injury associated with the combination of amoxicillin and clavulanic acid and amoxicillin alone were 1.7 (1.1-2.7) and 0.3 (.02-0.5) per 10 000 prescriptions, respectively. The rate ratios and 95% CIs of acute liver injury for amoxicillin and clavulanic acid together compared with amoxicillin alone were 6.3 (3.2-12.7) for all patients and 8.4 (3.6-20.8) for patients presenting with jaundice. Among users of amoxicillin and clavulanic acid together, the risk of developing acute liver injury was more than 3 times greater after a course of 2 or more consecutive prescriptions than after a single course of therapy. The risk also increased with age among users of amoxicillin and clavulanic acid together. The combination of advancing age and repeated prescriptions resulted in a risk of developing acute liver injury greater than 1 per 1000 users of amoxicillin and clavulanic acid together.

摘要

背景

阿莫西林-克拉维酸联合用药相关的肝炎和黄疸于1988年首次被发现。自那时起,已有大量病例报告和病例系列发表,但对此风险尚无精确估计。

方法

在英国进行一项回顾性队列研究,以评估阿莫西林与克拉维酸联合用药相关的急性肝损伤风险,并与单独使用阿莫西林的风险进行比较。数据来源于一个队列,其中93433名使用阿莫西林-克拉维酸联合药物的患者以及360333名单独使用阿莫西林的患者,年龄在10至79岁之间,随访时间为1991年至1992年。在查阅计算机文件中记录的疑似肝损伤患者信息后,向主治全科医生索要了177名患者的临床记录。

结果

共有35例特发性急性肝损伤病例。无一例死亡。单独使用阿莫西林的患者中有14例急性肝损伤。半数病例的肝损伤类型为肝细胞性。阿莫西林与克拉维酸联合使用的患者中有21例急性肝损伤。四分之三病例的肝损伤类型为胆汁淤积性。阿莫西林与克拉维酸联合用药以及单独使用阿莫西林发生急性肝损伤的发病率及95%置信区间(CI)分别为每10000张处方1.7(1.1 - 2.7)和0.3(0.02 - 0.5)。阿莫西林与克拉维酸联合使用相比单独使用阿莫西林,急性肝损伤的率比及95%CI在所有患者中为6.3(3.2 - 12.7),在出现黄疸的患者中为8.4(3.6 - 20.8)。在阿莫西林与克拉维酸联合使用的患者中,连续使用2个或更多疗程后发生急性肝损伤的风险比单疗程治疗后高出3倍多。在阿莫西林与克拉维酸联合使用的患者中,风险也随年龄增加而升高。年龄增长与重复用药相结合导致阿莫西林与克拉维酸联合使用的患者中急性肝损伤风险超过每1000人中有1例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验